Articles related to CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

The CRc rate was higher with GIL + AZA than with AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy. In addition, OS did not differ significantly between GIL + AZA and AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy.

A Q&A with John N. Allan, MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York, who discusses the changing role of prognostic markers, the usefulness of the markers, the biomarkers that should be part of standard testing, when patients should be tested, and much more.

Among doctors and researchers, the 2010 and 2017 versions of the European LeukemiaNet (ELN) recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults are broadly accepted. Researchers now have a better understanding of how AML develops from a molecular perspective, which has led to an update on the classification of the disease. Additionally, genomic diagnostics and the evaluation of measurable residual disease have advanced significantly, and new therapeutic agents like FLT3, IDH1, IDH2, and BCL2 inhibitors have been developed successfully. This update, which contains updated response criteria, therapy suggestions, and a revised ELN genetic risk classification, is a result of these developments.

Talking about the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel medications is Dr. Alexey V. Danilov, Professor and Co-Director of the Toni Stephenson Lymphoma Center at the City of Hope National Medical Center in Duarte, California.

Dr. Jonathan Abbas, Director of the Acute Leukemia and Blood Cancer Program with Tennessee Oncology in Nashville, shares key strategies and considerations for managing patients with t-AML and AML-MRC.

Major advances in the understanding of acute myeloid leukemia (AML) has prompted the need for this update, which includes a revised European LeukemiaNet (ELN) genetic risk classification, revised response criteria, and treatment recommendations from the 2010 and 2017 editions.